AnaptysBio Inc (NASDAQ:ANAB) saw unusually-strong trading volume on Monday after Royal Bank of Canada raised their price target on the stock to $108.00. Royal Bank of Canada currently has an outperform rating on the stock. Approximately 1,927,700 shares were traded during trading, an increase of 770% from the previous session’s volume of 221,524 shares.The stock last traded at $91.96 and had previously closed at $88.75.
A number of other research firms also recently weighed in on ANAB. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target on the stock in a research note on Friday, November 10th. JMP Securities raised their target price on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Wedbush reissued a “positive” rating and issued a $82.00 target price (up previously from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Credit Suisse Group raised their target price on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Finally, Jefferies Group started coverage on shares of AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $88.00.
Several hedge funds have recently modified their holdings of ANAB. TIAA CREF Investment Management LLC purchased a new position in shares of AnaptysBio in the 1st quarter valued at $227,000. Geode Capital Management LLC acquired a new stake in AnaptysBio during the 1st quarter valued at $1,522,000. Bank of America Corp DE acquired a new stake in AnaptysBio during the 1st quarter valued at $123,000. Schwab Charles Investment Management Inc. grew its holdings in AnaptysBio by 94.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock valued at $465,000 after purchasing an additional 9,414 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in AnaptysBio during the 2nd quarter valued at $436,000. 75.48% of the stock is currently owned by institutional investors and hedge funds.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. equities research analysts predict that AnaptysBio Inc will post -1.72 earnings per share for the current year.
WARNING: “AnaptysBio (ANAB) Sees Strong Trading Volume on Analyst Upgrade” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/12/18/anaptysbio-anab-sees-strong-trading-volume-on-analyst-upgrade.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.